Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: China-Canada Joint Health Research Initiative

McMaster University

$150,000.00

Induction of autophagic cell death: a potential therapeutic strategy against childhood AML by rapamycin and transferrin receptor antibody

EF 2008-09

Résumé
The typical treatment for childhood acute myeloid leukemia (AML) is intensive chemotherapy with several drugs that are often toxic to patients. As a result, treatment-related death in childhood AML remains significant problems. Furthermore, half as many children likely to suffer relapse following standard therapy and many of them develop resistance to subsequent treatment with the same chemotherapeutic drugs. Thus, novel approaches are needed to overcome the problem. We propose to evaluate a combined therapy using two established agents that may kill AML cells through a pathway different from the one used by conventional chemotherapies. Since this approach is to target a shared cell death pathway, our studies will help develop an alternative therapy not only for childhood AML in particular, but also for other tumors in general.
Programme
China-Canada Joint Health Research Initiative
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
182645
Name
Wan Yonghong
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
National Natural Science Foundation of China (Haidian, Beijing)
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Induction of autophagic cell death: a potential therapeutic strategy against childhood AML by rapamycin and transferrin receptor antibody
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
China-Canada Joint Health Research Initiative
Keyworddelim
Antibody; Autophagy; Childhood Acute Myeloid Leukemia; Rapamycin; Transferrin Receptor; Xenograft
Abstract
The typical treatment for childhood acute myeloid leukemia (AML) is intensive chemotherapy with several drugs that are often toxic to patients. As a result, treatment-related death in childhood AML remains significant problems. Furthermore, half as many children likely to suffer relapse following standard therapy and many of them develop resistance to subsequent treatment with the same chemotherapeutic drugs. Thus, novel approaches are needed to overcome the problem. We propose to evaluate a combined therapy using two established agents that may kill AML cells through a pathway different from the one used by conventional chemotherapies. Since this approach is to target a shared cell death pathway, our studies will help develop an alternative therapy not only for childhood AML in particular, but also for other tumors in general.
Competitiondate
200903
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wan, Yonghong; Huang, Bo
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Human Dev &Child &Yth~ $150,000~ $0~